Angiogenesis and ovarian cancer

Clinical and Translational Oncology

Volumn 11, Issue 9, 2009, Pages 564-571

  Gómez Raposo, César ^a   Mendiola, Marta ^b   Barriuso, Jorge ^c   Casado, Enrique ^a   Hardisson, David ^a   Redondo, Andrés ^a  

^a Infanta Sofía San Sebastián de los Reyes ^*  (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Angiogenesis; Ovarian cancer; Prognostic factors

Indexed keywords

HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; NOS2A PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; BIOLOGICAL MODEL; CARCINOMA; FEMALE; GENETICS; HUMAN; NEOVASCULARIZATION (PATHOLOGY); OVARY; OVARY TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

CARCINOMA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73349114642     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0406-y     Document Type: Article

References (73)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171
3. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186
4. Folkman J, Watson K, Ingber D et al (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61
5. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
6. Ramakrishnan S, Subramanian IV, Yokoyama Y et al (2005) Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8:169-182
7. Abu-Jawdeh GM, Faix JD, Niloff J et al (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74:1105-1115
8. Waltenberger J, Claesson-Welsh L, Siegbahn A et al (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995
9. Ferrara N (1995) The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36:127-137
10. Nakanishi Y, Kodama J, Yoshinouchi M et al (1997) The expression of vascular endothelial growth factor and transforming growth factor-ß associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 16:256-262
11. Masood R, Cai J, Zheng T et al (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913
12. Inan S, Vatansever S, Celik-Ozenci C et al (2006) Immunolocalizations of VEGF, its receptors fl t-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 21:1055-1064
13. Trinh XB, Tjalma WAA, Vermeulen PB et al (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100:971-978
14. Chen H, Ye D, Xie X et al (2004) VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94:630-635
15. Fan F, Wey JS, McCarty MF et al (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:2647-2653
16. Welsh JB, Zarrinkar PP, Sapinoso LM et al (2001) Analysis of gene expression profi les in normal and neoplastic ovarian tissue samples identifi es candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98:1176-1181
17. Byrne AT, Ross L, Holash J et al (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodelling in an ovarian cancer model. Clin Cancer Res 9:5721-5728
18. Jiang H, Feng Y (2006) Hypoxia-inducible factor 1alpha (HIF-1?) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer 16[Suppl 1]:405-412
19. Zhu G, Saed GM, Deppe G et al (2004) Hypoxia up regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. Gyn Oncol 94:422-426
20. Kumaran GC, Jayson GC, Clamp AR (2009) Antiangiogenic drugs in ovarian cancer. Br J Cancer 100:1-7
21. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
22. Osada R, Horiuchi A, Kikuchi N et al (2006) Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: Increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37:1414-1425
23. Buckanowich RJ, Sasaroli D, O'Brien-Jenkins A et al (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25:852
24. Lecouter J, Lin R, Ferrara N (2004) EG-VEGF: A novel mediator of endocrine-specific angiogenesis, endothelial phenotype, and function. Ann N Y Acad Sci 50:50-57
25. Barton DP, Cai A, Wendt K et al (1997) Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 3:1579-1586
26. Davidson B, Goldberg I, Gotlieb WH et al (2002) The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 187:39-45
27. Sako A, Kitayama J, Yamaguchi H et al (2003) Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 115:113-120
28. Miyamoto S, Hirata M, Yamazaki A et al (2004) Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64:5720-5727
29. Calza L, Giardino L, Giuliani A et al (2001) Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Natl Acad Sci USA 98:4160-4165
30. Rosano L, Cianfrocca R, Masi S (2009) ß-Arrestin links endothelin A receptor to ß-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106:2806-2811
31. Davidson B, Goldberg I, Reich R et al (2003) AlphaV-and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90:248-257
32. Lassus H, Sihto H, Leminen A et al (2004) Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 91:2048-2055
33. Sariban E, Sitaras NM, Antoniades HN et al (1988) Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines. J Clin Invest 82:1157-1164
34. Xu L, Fidler IJ (2000) Interleukin 8: An autocrine growth factor for human ovarian cancer. Oncol Res 12:97-106
35. Kamba T, Tam BY, Hashizume H et al (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-576
36. Seaman S, Stevens J, Yang MY et al (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11:539-554
37. Vermulen PB, Gasparini G, Fox SB et al (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantifi cation in solid human tumours. Eur J Cancer 38:1564-1579
38. Rubatt JM, Darcy KM, Hutson A et al (2009) Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncolgoy Group study. Gynecol Oncol 112:469-474
39. Alvarez AA, Krigman HR, Whitaker RS et al (1999). The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587-591
40. Hollingsworth HC, Kohn EC, Steinberg SM et al (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41
41. Abulafia O, Triest WE, Sherer DM (1997) Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 177:541-547
42. Taskiran C, Erdem O, Onan A et al (2006) The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 16:1789-1793
43. Gadducci A, Viacava P, Cosio S (2003) Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res 23:549-556
44. Gadducci A, Ferrero A, Cosio S et al (2006) Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res 26:3925-3932
45. Goodheart MJ, Ritchie JM, Rose SL et al (2005) The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11:3733-3742
46. Goodheart MJ, Vasef MA, Sood A et al (2002) Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol 86:85-90
47. Fonsatti E, AltomonteM, Nicotra MR et al (2003) Endoglin (CD105): A powerful therapeutic target on tumor-associated angiogenic blood vessels. Oncogene 22:6557-6563
48. El-Gohary YM, Silverman JF, Olson PR et al (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127:572-579
49. Tsujie M, Uneda S, Tsai H et al (2006) Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 29:1087-1094
50. Shen GH, Ghazizadeh M, Kawanami O et al (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196-203
51. Paley PJ, Staskus KA, Gebhard K et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106
52. Kassim SK, El-Salahy EM, Fayed ST et al (2004) Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer. Clin Biochem 37:363-369
53. Hefler LA, Mustea A, Konsgen D et al (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13:898-901
54. Hartenbach EM, Olson TA, Goswitz JJ et al (1997) Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121:169-175
55. Hefler LA, Mustea A, Könsgen D et al (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13:898-901
56. Mohammadi M, Ollier WE, Hutchinson IV (2003) A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells. Hum Immunol 64:S125
57. Duncan TJ, al-Attar A, Rollan P et al (2008) Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies? Clin Cancer Res 14:3030-3035
58. Yamamoto S, Konishi I, Mandai M et al (1997) Expression of vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227
59. Ogawa S, Kaku T, Kobayashi H et al (2002) Prognostic significance of microvessel density, vascular endothelial growth factor expression in ovarian carcinoma: Special review for clear cell adenocarcinoma. Cancer Lett 176:111-118
60. Nishida N, Yano H, Komai K et al (2004). Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101:1364-1374
61. Ueda M, Terai Y, Kumagai K et al (2001) Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 82:162-166
62. Yokohama Y, Charnock-Jones DS, Licence D et al (2003) Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88:237-244
63. Jeon BH, Jang C, Han J et al (2008) Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 68:1100-1109
64. Heinzman JM, Brower SL, Bush JE (2008) Comparison of angiogenesis-related factor expression in primary tumor cultures under normal and hypoxic growth conditions. Cancer Cell Int 8:11
65. Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6:521-534
66. Engels K, du Bois A, Harter P et al (2009) VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol 62:448-454
67. Osada R, Horiuchi A, Kikuchi N et al (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: Nuclear expression of hypoxia inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38:1310-1320
68. Henriksen R, Funa K, Wilander E et al (1993) Expression and prognostic significance of plateletderived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554
69. Lin CQ, Singh J, Murata K et al (2000) A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 60:1332-1340
70. Schindl M, Schoppmann SF, Ströbel T et al (2003) Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 9:779-785
71. Martiny-Baron G, Korff T, Schaffner F et al (2004) Inhibition of tumor growth and angiogenesis by soluble ephb4. Neoplasia 6:248-257
72. Wu Q, Suo Z, Kristensen GB et al (2006) The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 102:15-21
73. Mendiola M, Barriuso J, Redondo A et al (2008) Angiogenesis-related gene expression profi le with independent prognostic value in advanced ovarian carcinoma. PLoS One 3: E4051